Skip to main content

NET not compulsory for PhD

The University Grants Commission (UGC) has amended two sets of its regulation. It has relaxed the minimum eligibility norms (NET) for the appointment of assistant professors and has granted more time for women and differently-abled scholars to complete their Ph.D and M.Phil degrees.

HRD Minister Smriti Irani announced these two new amendments in a press conference on  April 12. The idea behind these amendments is to grant lectureship to non-NET students and to promote the entry of more women and differently-abled students into the field of research.

NET not compulsory
Till now, according to the 2009 regulations, a candidates would have required at least a post-graduate or an MPhil degree along with a cleared NET or SET (State-level eligibility test) as minimum eligibility for appointment in colleges and universities as teachers and lecturers. But now, those who have completed a Ph.D or registered for a Ph.D before 2009 would be eligible for lectureship without clearing the NET, reported by The Huffington Post.

The decision has been taken keeping in mind the creation  of more job opportunities in teaching field.

However, a candidate should adhere to certain conditions to be exempted of NET.  The candidate’s Ph.D degree should be awarded in regular mode and the research thesis should have been evaluated by at least two external examiners. Also, the candidate should have appeared for viva-voce and have published at least two papers based on the Ph.D thesis in research journals.

Ph.D and M.Phil tenure relaxed
The UGC would now allow women and differently-abled students to complete their Ph.D in eight years instead of the present six years and M.Phil in three years instead of two years.

Women candidates will also be provided maternity and child care leave for up to 240 days in the entire duration of their M.Phil or Ph.D degrees, as reported by IndiaTVNews.

In case of relocation of a woman Ph.D or M.Phil scholar due to marriage or otherwise, her research data shall be allowed to be transferred to the university to which the scholar intends to relocate, though subject to certain norms.

The Logical Indian hopes the decisions taken by the UGC and HRD ministry turns out to be good in long run. Now we all have to wait and for the end results of this amendments.
 

Comments

Popular posts from this blog

Pharma Companies HR contact information

Dear viewers of my blog, I am happy to share the HR contact details of Pharmaceutical companies. Contact Details Of Pharma HRs : Zaydus cadila-Goa gajendravernekar@zayduscadila.com 09623458512/08326615143 Teva-Goa Maryann.Braganza@teva.co.in sanjay.pandit@teva.co.in 0832 6685538 Glenmark-Goa Vittal hebbalkar hr executivr - 9923476869 anupbannatti@glenmark-generics.com 09604151586 Watson-Goa Jyosna.bagule@watsonpharm.co.in runa.divkar@watsonpharm.co.in goa@watsonpharm.co.in 0832 6690666/777 Unichem Labs-Goa abhiram.panshikar@unichemlabs.com R&D  suraj.jadhav@unichemlabs.com vikas.parkar@unichemlabs.com Indico-Goa goahplc@Indoco.com varun.keny@indoco.com anand.ingole@Indoco.com 0832 6624109 Encube-Goa hr@encubeethicals.com nidhi.b@encubeethicals.com 8322392223 Torrent pharma-Ahmdabad mayurdesai@torrentpharma.com 9879603921/22/23/24 Emcure-pune RPKulkarni@emcure.co.in           Kishor.Mule@emcur...

Corona virus (Covid-19)

The only way one can combat with Covid-19 is by building one’s immunity & staying healthy by proper hygiene Best medicines for immunity development could be multivitamin pills with zinc,and best foods could be #freshfruits #vegetables. #Mangoes #lemon #oranges are could be the best.

Biogen to seek approval for high-dose version of Spinal Muscular Atrophy stalwart Spinraza (Nusinersen) after trial win

Biogen, which was first to score an endorsement in Spinal Muscular Atrophy (SMA) in 2016, is endeavoring to address it with a higher portion variant of Spinraza #(Nusinersen). On Wednesday, the organization uncovered that a part of its stage 2/3 Commit concentrate on met its essential endpoint, as a higher portion of Spinraza worked on the engine capability of treatment-innocent newborn children with SMA. The review contrasted the high-portion routine with a coordinated, untreated hoax control bunch from the stage 3 Charm study, which empowered Spinraza's unique endorsement. In the Commit preliminary accomplice, 75 patients were randomized 2:1 to get the higher-portion routine or the FDA-endorsed dose of 12 mg, which incorporates four beginning medicines, trailed by support dosages like clockwork. While the high-portion form of Spinraza met the preliminary's endpoint contrasted with joke, the outcomes too "moved in favor" of the investigational routine contrasted with...